Mecasermin, from Tercica Europe Limited, for treatment of primary insulin-like growth factor- 1 deficiency due to molecular or genetic defects (review time: day 87) ----------------------------- INSM http://www.emea.europa.eu/pdfs/human/comp/18025106en.pdf
Mecasermin rinfabate, from Insmed Europe Ltd., for treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects (review time: day 30)
Now all this gets even more interesting.. apparently the US news did reach the US as well because additional questions were presented, and TRCA was asked an opinion there.. so were there additional questions for TRCA where there are none yet for INSM? (considering INSM was rushed through the COMP panel in 30 days, where TRCA was held up for 87 days)
the DATE of this pdf creation is: (found in document properties ->description in adobr acrobat pro) Created : 13-6-2006 at 10:54:45 Last modified: 13-6-2006 at 12:09:45
Hmmmmmm So this new discussion is AFTER insmed was approved as orphan designation as well..and after insmed should have been moved to the CHMP agenda as well..